Reference
Tricco AC, et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ 349: g5459, 1 Oct 2014. Available from: URL: http://dx.doi.org/10.1136/bmj.g5459
Rights and permissions
About this article
Cite this article
Insulin glargine, insulin detemir likely "more costly". PharmacoEcon Outcomes News 713, 18 (2014). https://doi.org/10.1007/s40274-014-1603-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1603-7